Skip to main content
Skip to main menu

Slideshow

Gregory P. Strauss

Blurred image of the arch used as background for stylistic purposes.
Associate Professor
Clinical Program

*Note: Dr. Strauss will not be reviewing applications for graduate students applying during the fall 2022 cycle/fall 2023 start date*

Lab Website:

Clinical Affective Neuroscience Laboratory (CAN Lab): https://ugacanlab.com

About:

Dr. Strauss directs the UGA Clinical Affective Neuroscience Laboratory and Georgia Psychiatric Risk Evaluation Program (G-PREP).

Research Interests:

Dr. Strauss’ program of research examines the phenomenology, etiology, assessment, and treatment of negative symptoms in schizophrenia and youth at clinical high-risk for psychosis.

Negative symptoms are reductions in motivation, emotion, and behavior that are associated with a range of poor clinical outcomes. Unfortunately, interventions have proven ineffective at remediating negative symptoms. The identification of novel neurophysiological and psychological mechanisms that can serve as treatment targets for pharmacological and psychosocial treatments is therefore a significant need in our field, as is the development of new assessments that can measure the construct adequately. Research in the CAN Lab aims to address these needs in the field.

Phenomenology: Our research on phenomenology has focused on determining: 1) whether negative symptoms are best conceptualized as a categorical, dimensional, or hybrid construct; 2) how many domains are part of the negative symptom construct. Our findings indicate that negative symptoms are a hybrid dimensional-categorical construct, such that people with schizophrenia differ in kind above a certain symptom threshold of negative symptoms. Beyond this threshold, negative symptom severity is predictive of individual differences in external correlates, such as cognitive impairment and functional outcome. However, negative symptoms are not unidimensional, as suggested by early factor analytic studies. Rather, negative symptoms are multi-dimensional and these dimensions have distinct pathophysiological and psychological mechanisms. Early work that we and others conducted on the factor structure of negative symptoms supported a two dimensional conceptualization, with dimensions reflecting diminished expression (EXP) and motivation and pleasure (MAP). However, using more advanced mathematical approaches, we have recently found that the construct is best considered in relation to 5 distinct domains (anhedonia, avolition, asociality, blunted affect, alogia). This 5 domain structure has been found across the 3 most contemporary measures (BNSS, CAINS, SANS), across multiple cultures and languages (e.g., English, Italian, Spanish, Chinese, Korean, Japanese), using multiple mathematical techniques (e.g., CFA, network analysis), and across chronic and clinical high-risk phases of illness. Recently, we have been examining whether these 5 domains have distinct pathophysiological mechanisms and clinical correlates to determine whether a change is needed for DSM-5 negative symptom diagnostic criteria and whether the 5 domains reflect distinct treatment targets.

Etiology: The primary focus of our research is on identifying mechanisms underlying negative symptoms. Our initial studies examined the most straightforward explanation for avolitional symptoms in schizophrenia- that patients fail to engage in activities because they do not find them rewarding; however, this hypothesis was not supported because subjective and neurophysiological response to rewarding stimuli is intact in schizophrenia. This finding lead us to explore why apparently normal hedonic responses do not translate into goal-directed behavior in schizophrenia. We have demonstrated that abnormalities in several aspects of reward processing (e.g., reinforcement learning, effort-cost computation, value representation, uncertainty-driven exploration) that are driven by aberrant cortico-striatal interactions may prevent intact hedonic responses from influencing decision-making processes that are needed to initiate motivated behavior. We have also demonstrated that avolition is associated with dysfunctional cognition-emotion interactions (e.g., memory, attention), emotion regulation abnormalities, social cognition impairments, a reduction in the positivity offset, and anhedonic beliefs. In recent years, we have expanded our work on the etiology of negative symptoms into the psychosis prodrome, where we have found that reward processing deficits predict the severity of negative symptoms in at-risk youth. However, due to the greater propensity for depression in this phase of illness, hedonic deficits play a greater role in negative symptoms in the prodrome than in schizophrenia, propagating forward and creating deficits in other aspects of reward processing that also occur in schizophrenia. We are currently conducting longitudinal studies to determine which reward processing mechanisms associated with negative symptoms predict the emergence of psychotic disorders versus other conditions (e.g., depression) in youth at clinical high-risk for psychosis. Most recently, we are evaluating environmental contributions to negative symptoms in relation to a bioecosystem theoretical framework (see Strauss, 2021: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.655471/full).

Assessment: The development of next-generation negative symptom assessments has been another key focus of research in the CAN Lab. In 2005, NIMH held a consensus development conference on negative symptoms. A key conclusion of this meeting was that new rating scales were needed to increase chances of observing treatment effects. Two scales resulted from this initiative. Dr. Strauss was co-developer of one of these scales along with Brian Kirkpatrick, the Brief Negative Symptom Scale (BNSS), and served as PI on multiple studies validating the scale. Our lab has also led efforts in translating the BNSS into other languages  and facilitating its primary intended use as an outcome measure in industry sponsored clinical trials. Most recently, Dr. Strauss and Dr. Vijay Mittal co-developed and validated a new scale for those at clinical high-risk for psychosis, the Negative Symptom Inventory-Psychosis Risk (NSI-PR). The measure is being modified and validated in a multi-site R01. Our lab has also begun developing and validating new digital phenotyping measures. This includes active (e.g., EMA surveys, videos, tasks) and passive (e.g., geolocation, accelerometry, ambient sound) negative symptom measurements taken from smart phones and smartbands (ambulatory psychophysiology, accelerometry). We are also exploring whether these tools hold promise as novel risk prediction and monitoring assessments for predicting conversion to a psychotic disorder among clinical high-risk youth.

Treatment: In collaboration with colleagues at multiple institutions, we have conducted clinical trials examining the efficacy of pharmacological treatments for negative symptoms. Based on our studies showing a role for endogenous oxytocin in social cognition deficits and negative symptoms, we examined the efficacy of oxytocin as a treatment for asociality. In multiple clinical trials, oxytocin was not more effective than placebo, and we recently extended this work by demonstrating that combining oxytocin with psychosocial treatment had no added benefit over psychosocial treatment alone. We have partnered with pharmaceutical companies to investigate the efficacy of pharmacological agents for negative symptoms, testing differential efficacy for negative symptom domains. Using a network analytic approach, we recently found that avolition may be the most central symptom to target to produce global improvements in the entire negative symptom construct. Currently, we are exploring the efficacy of a novel app-based cognitive training intervention for improving emotion regulation abnormalities in an R61 grant from NIMH. We are examining whether increased prefrontal activation leads to better emotion regulation, and whether this translates into reductions in negative symptoms, positive symptoms, and improved functional outcome.

Research Methods:

Primary/Used for Several years: Electroencephalography (EEG), eye tracking, pupillometry, digital phenotyping/ecological momentary assessment

Secondary/Newer: Functional Magnetic Resonance Imaging (fMRI), peripheral psychophysiology (electrodermal activity, electrocardiography), blood and saliva draws for biomarkers (e.g., cytokines, cortisol, oxytocin), computational modeling 

Lab Website:

Clinical Affective Neuroscience Laboratory (CAN Lab): https://ugacanlab.com

Grants:

ACTIVE 

1. U01MH124639 (PI: SW Woods)   09/08/2020-06/30/2025

NIMH $1,732,983; Total funding across all sites: $52,000,000

ProNET: Psychosis Risk Outcomes Network  

This multinational study evaluates biomarkers and clinical factors giving rise to the development of psychotic disorders in those at clinical high-risk for psychosis   

Role: Site PI

 

2. R21 –MH122863 (PI: GP Strauss)  04/01/2020-03/31/2022

NIMH $440,650

Computationally modeling the failure of effort to become a secondary reinforcer in schizophrenia

This grant uses computational modeling and pupillometry to test the novel hypothesis that avolition in schizophrenia results from a failure of effort to become a secondary reinforcer

Role: PI

 

3. R01MH116039-02S1 (PI: Ivan Ruiz) 12/01/2019-11/30-2021

NIMH  $116,282

Prodromal Inventory for Negative Symptoms (PINS): A Development and Validation Study  

This diversity supplement awards a fellowship for Strauss lab graduate student Ivan Ruiz to conduct a sub-study on cognitive effort mechanisms of avolition in youth with prodromal syndromes and obtain additional clinical and neuroscience based training.

Role: Mentor 

 

4.  R01-MH120092 (PI: GP Strauss)  04/01/2020-03/31/2025

NIMH  $2,080,177

4/5 CAPER: Computerized Assessment of Psychosis Risk

This grant develops and validates a novel computerized screening battery for the early identification of psychosis among youth with prodromal syndromes.

Role: PI

 

5. R61-MH121560 (PI GP Strauss)  04/01/2020 – 03/31/2025

NIMH  $2,997,345

Cognitive training for emotion regulation in psychotic disorders. 

This grant examines the efficacy of a novel app-based cognitive training program for enhancing the proximal target of emotion regulation via a direct mechanistic effect on increasing prefrontal activation, as well as a distal target of improving symptoms and functional outcome. 

Role: PI

 

6. R21-MH119438 (PI GP Strauss)   09/01/2019-08/31/2021 

NIMH   $415,250

Mechanisms Underlying Emotion Regulation Abnormalities in Youth at Clinical High-Risk for Psychosis 

This grant examines mechanisms underlying emotion regulation abnormalities at the identification, selection, and implementation stages in youth at clinical high-risk for psychosis using EMA, ambulatory psychophysiology, EEG, pupillometry, and eye-tracking.

Role: PI

 

7. R01-MH116039 (PI GP Strauss)   03/01/2019-11/30/2023

NIMH  $2,969,883

Prodromal Inventory for Negative Symptoms (PINS): A Development and Validation Study  

This grant develops and validates novel methods for assessing negative symptoms in youth at clinical high-risk for psychosis to enhance risk prediction algorithms 

Role: PI  

Selected Publications:

* = Student/Trainee (Publications are from the past year only)

In Press/2022

1. Narkhede*, S.M., Luther*, L., Raugh*, I.M., Knippenberg*, A.R., Zamani Esfahlani, F., Sayama, H., Cohen, A.S., Kirkpatrick, B., Strauss, G.P. (2022). Machine learning identifies digital phenotyping measures most relevant to negative symptoms in psychotic disorders: Implications for clinical trials. Schizophrenia Bulletin, 45, 425-436.

 

2. Gupta, T., Haase, C.M., Strauss, G.P., Cohen, A.S., Ricard, J.R., Mittal, V.A. (in press). Alterations in facial expressions of emotion: Determining the promise of ultra-thin slicing approaches and comparing human and automated coding methods in psychosis risk. Emotion.

 

3. Macdonald*, K.I., Spilka*, M.J., Bartolomeo*, L.A., Raugh*, I.M., Berglund*, A.M., Strauss, G.P. (in press). Adherence to recommended health and social distancing precautions during the COVID-19 pandemic in individuals with schizophrenia and youth at clinical high-risk for psychosis. Schizophrenia Research.

 

4. Raugh*, I.M., Strauss, G.P. (in press). Deconstructing emotion regulation in schizophrenia: The nature and consequences of abnormalities at the identification stage. European Archives of Psychiatry and Clinical Neuroscience.

 

5. Macfie, W.G., Spilka, M., Bartolomeo, L.A., Gonzalez, C.M., Strauss, G.P. (in press). Emotion Regulation And Social Knowledge In Youth At Clinical High Risk For Psychosis And Outpatients With Chronic Schizophrenia: Associations With Functional Outcome And Negative Symptoms. Early Intervention in Psychiatry.

 

6. Collins, D., Luther, L., Raugh, I.M., Condray, R., Allen, D.N., Strauss, G.P. (in press). Environmental contributions to negative symptoms: Exploring the role of disability benefits and interactions with social, political, and legal exosystems. Schizophrenia Bulletin.

 

7. Spilka, M. J., Keller, W. R., Buchanan, R. W., Gold, J. M., Koenig, J. I., Strauss, G. P. (in press). Endogenous oxytocin levels are associated with facial emotion recognition accuracy but not gaze behavior in individuals with schizophrenia. Acta Psychiatrica Scandinavica.

 

8. Strauss, G.P., Luther, L., Raugh, I.M., Zhang, L., Chapman, H.C., Allen, D.N., Kirkpatrick, B., Cohen, A.S. (in press). Validation of accelerometry as a digital phenotyping measure of negative symptoms in schizophrenia. Schizophrenia.

 

9. Zhang, L., & Strauss, G.P. (in press). Adaptive and maladaptive consequences of increased social media and internet use during the COVID-19 pandemic in schizophrenia. Schizophrenia Research.

 

10. Davidson, M., Saoud, J., Staner, C., Noel, N., Werner, S., Luthringer, E., Walling, D., Weiser, M., Harvey, P.D., Strauss, G.P., Luthringer, R., (in press). Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia. Schizophrenia Bulletin.

 

11. Browne, J., Harvey, P.D., Buchanan, R.W., Kelly, D.L., Strauss, G.P., Gold, J.M., Holden, J.L. Granholm, E., (2022). A Longitudinal Examination of Real-World Sedentary Behavior in Adults with Schizophrenia-Spectrum Disorders in a Clinical Trial of Combined Oxytocin and Cognitive Behavioral Social Skills Training. Behavioral Sciences, 12(3), 60.

 

12. Cowan, T., Cohen, A. S., Raugh*, I. M., & Strauss, G. P. (2022). Ambulatory audio and video recording for digital phenotyping in schizophrenia: Adherence & data usability. Psychiatry Research, 114485

 

13. Spilka*, M. J., Keller, W. R., Buchanan, R. W., Gold, J. M., Koenig, J. I., & Strauss, G. P. Endogenous oxytocin levels are associated with facial emotion recognition accuracy but not gaze behavior in individuals with schizophrenia (in press). Acta Psychiatrica Scandinavica.

 

14. Cohen, A.S., Rodriguez, Z., Warren, K.K., Cowan, T.M., Masucci, M.D., Ganrud, E., Holmlund, T.B., Chandler, C., Foltz, P.W., Strauss, G.P. (in press). Natural language processing and psychosis: On the need for comprehensive psychometric evaluation. Schizophrenia Bulletin.

 

15. Turner, J.A., Calhoun, V.D., Thompson, P.M., Jahanshad, N., Ching, C.R., Thomopoulos, S.I., Verner, E., Strauss, G.P., Ahmed, A.O., Turner, M.D. and Basodi, S., (2021). ENIGMA+ COINSTAC: improving findability, accessibility, interoperability, and re-usability. Neuroinformatics, pp.1-15.

 

16. Cowan, T., Masucci, M. D., Gupta, T., Haase, C. M., Strauss, G. P., & Cohen, A. S. (2022). Computerized analysis of facial expressions in serious mental illness. Schizophrenia Research, 241, 44-51.

 

17. Ahmed, A. O., Kirkpatrick, B., Granholm, E., Rowland, L. M., Barker, P. B., Gold, J. M., ... & Strauss, G. P. (2022). Two Factors, Five Factors, or Both? External Validation Studies of Negative Symptom Dimensions in Schizophrenia. Schizophrenia bulletin.

 

18. Miller, M. L., Raugh,* I. M., Strauss, G. P., & Harvey, P. D. (2022). Remote Digital Phenotyping in Serious mental Illness: Focus on Negative Symptoms, Mood Symptoms, and Self-Awareness. Biomarkers in Neuropsychiatry, 100047.

 

19. Bartolomeo*, L. A., Raugh*, I. M., & Strauss, G. P.(2022). Deconstructing emotion regulation in schizophrenia: The nature and consequences of abnormalities in monitoring dynamics. Schizophrenia Research, 240, 135-142.

 

 

2021

1. Strauss, G.P. (2021). A Bioecosystem Theory of Negative Symptoms in Schizophrenia. Frontiers in Psychiatry, 12: 655471.

 

2. Woods SW,Bearden CE, Sabb FW, Stone WS, Torous J, Cornblatt BA, Perkins DO, Cadenhead KS, Addington J, Powers III AR, Mathalon DH, Calkins ME, Wolf DH, Corcoran CM, Horton LE, Mittal VA, Schiffman JE, Ellman LE, Strauss GP, Mamah D, Choi J, Pearlson GD, Shah JL, Fusar-Poli P, Arango C, Perez J, Koutsouleris N, Wang J, Kwon JS, Walsh BC, McGlashan TH, Hyman SE, Gur RE, Cannon TD, Kane JM, Anticevic A. (2021). Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. Schizophrenia Research, 227, 10-17.

 

3. Cohen, A. S., Schwartz, E. K., Le, T., Cowan, T. M., Kirkpatrick, B., Raugh*, I. M., Strauss, G.P. (2021). Digital phenotyping of negative symptoms: The relationship to clinician ratings. Schizophrenia Bulletin, 23, 44-53.

 

4. Gupta, T., Cowan, H.R., Strauss, G.P., Walker, E.F., Mittal, V.A. (2021). Deconstructing negative symptoms in individuals at clinical high-risk for psychosis: Evidence for volitional and diminished emotionality subgroups that predict clinical presentation and functional outcome. Schizophrenia Bulletin, 47, 54-63.

 

5. Chang, W.C., Strauss, G.P., Ahmed, A.O., Wong, S.C.Y., Chan, J.K.N., Lee, E.H.M., Chan, S.K.W., Hui, C.L.M., James*, S.H., Chapman*, H.C., Chen, E.Y.H. (2021). The latent structure of negative symptoms in individuals with attenuated psychosis syndromes and first episode psychosis: Support for the 5 consensus domains. Schizophrenia Bulletin, 47, 386-394.

 

6. Strauss, G.P., Bartolomeo, L.A., Harvey, P.D. (2021). Avolition as the core negative symptom in schizophrenia: Relevance to pharmacological treatment development. Npj Schizophrenia, 26: 16.

 

7. Sun, J., Ka, ECW, Strauss, GP, Ahmed, AO, Chui WWH, Chow, JSY (2021). Validation of the traditional script chinese version of the Brief Negative Symptom Scale. Asian Journal of Psychiatry, 55,: 102522.

 

8. Strauss, G.P., Datta, R., Armstrong, W., Raugh*, I.M., Kraguljac, N.V., Lahti, A.C. (2021). Reinforcement learning abnormalities in the attenuated psychosis syndrome and first episode psychosis. European Neuropsychopharmacology, 47, 11-19.

 

9. Pelletier-Baldelli, A., Strauss, G.P., Kuhney, F.S., Chun, C., Gupta, T., Ellman, L.M., Schiffman, J., Mittal, V.A. (2021). Perceived stress influences anhedonia and social functioning in a community sample enriched for psychosis-risk. Journal of Psychiatric Research, 135, 96-103.

 

10. Bartolomeo*, L.A., Chapman*, H.C., Raugh*, I.M., Strauss, G.P. (2021). Delayed discounting in youth at clinical high-risk for psychosis and adults with schizophrenia. Psychological Medicine, 51, 1898-1905.

 

11. Clay, K. B., Raugh, I. M., Bartolomeo, L. A., & Strauss, G. P. (2021). Defeatist performance beliefs in individuals at clinical high‐risk for psychosis and outpatients with chronic schizophrenia. Early Intervention in Psychiatry, 15(4), 865-873.

 

12. Kirkpatrick, B., Cohen, A., Bitter, I., & Strauss, G. P. (2021). Primary Negative Symptoms: Refining the Research Target. Schizophrenia Bulletin, 47(5), 1207-1210.

 

13. Buchanan RW, Kelly DL, Strauss GP, Gold JM, Weiner E, Zaranski J, Chen S, Blatt F, Holden J, Granholm E. (2021). Combined Oxytocin and Cognitive Behavioral Social Skills Training for Social Function in People With Schizophrenia. Journal of Clinical Psychopharmacology;41(3):236-43.

 

14. Silverstein SM, Thompson JL, Gold JM, Schiffman J, Waltz JA, Williams TF, Zinbarg RE, Mittal VA, Ellman LM, Strauss GP, Walker EF (2021). Increased face detection responses on the mooney faces test in people at clinical high risk for psychosis. npj Schizophrenia. 17;7(1):1-7.

 

15. Strauss, G. P., Macdonald*, K. I., Ruiz*, I., Raugh*, I. M., Bartolomeo*, L. A., & James*, S. H. (2021). The impact of the COVID-19 pandemic on negative symptoms in individuals at clinical high-risk for psychosis and outpatients with chronic schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 1-11.

 

16. Mittal, V. A., Bernard, J. A., Strauss, G. P., & Walther, S. (2021). New insights into sedentary behavior highlight the need to revisit the way we see motor symptoms in psychosis. Schizophrenia bulletin, 47(4), 877-879.

 

17. Sabe, M., Zhao, N., Crippa, A., Strauss, G. P., & Kaiser, S. (2021). Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials. International Journal of Neuropsychopharmacology, 24(8), 601-614.

 

18. Azis, M., Rouhakhtar, P. R., Schiffman, J. E., Ellman, L. M., Strauss, G. P., & Mittal, V. A. (2021). Structure of positive psychotic symptoms in individuals at clinical high risk for psychosis. Early intervention in psychiatry, 15(3), 505-512.

 

19. Strauss, G. P., Bartolomeo*, L. A., & Luther*, L. (2021). Reduced willingness to expend effort for rewards is associated with risk for conversion and negative symptom severity in youth at clinical high-risk for psychosis. Psychological Medicine, 1-8.

 

20. Raugh*, I. M., James*, S. H., Gonzalez*, C. M., Chapman*, H. C., Cohen, A. S., Kirkpatrick, B., & Strauss, G. P. (2021). Digital phenotyping adherence, feasibility, and tolerability in outpatients with schizophrenia. Journal of Psychiatric Research, 138, 436-443.

 

21. Gupta, T., Strauss, G. P., Cowan, H. R., Pelletier-Baldelli, A., Ellman, L. M., Schiffman, J., & Mittal, V. A. (2021). Secondary Sources of Negative Symptoms in Those Meeting Criteria for a Clinical High-Risk Syndrome. Biological Psychiatry Global Open Science, 1(3), 210-218.

 

22. Mittal, V. A., Walker, E. F., & Strauss, G. P. (2021). The COVID-19 Pandemic Introduces Diagnostic and Treatment Planning Complexity for Individuals at Clinical High Risk for Psychosis. Schizophrenia bulletin, 47(6), 1518-1523.

 

23. Mittal, V. A., Ellman, L. M., Strauss, G. P., Walker, E. F., Corlett, P. R., Schiffman, J., Woods, S. W., Powers, A. R., Silverstein, S. M., Waltz, J. A., Zinbarg, Z., Chen, S., Williams, T., Kenney, J., & Gold, J. M. (2021). Computerized assessment of psychosis risk. Journal of Psychiatry and Brain Science, 6, Article e210011

 

24. Tran*, T., Holland*, A. H., Zhang*, L., Raugh*, I. M., & Strauss, G. P. (2021). Social media and internet use is associated with both adaptive and maladaptive changes in mental health during the COVID-19 pandemic in youth at clinical high-risk for psychosis. Journal of Psychiatric Research, 147, 1-3.

Of note:

Philosophy of Graduate Training:

 I encourage my postdocs, graduate students, and employees to develop a sound theoretical knowledge base in our area of work, gain methodological expertise in the use of cognitive neuroscience methods (e.g., ERP, eye-tracking), build basic research skills (e.g., programming, writing, statistics), and develop strong clinical abilities that will facilitate their clinical research and practice (e.g., diagnostic and symptom interviewing, neuropsychology). I emphasize the importance of developing a niche area and help my trainees plan and design a series of independent studies that build upon one another, with the goal of creating their own independent program of research. I also invest time in the professional development of my trainees via regular meetings to discuss strategies for success at different stages of academic careers, and by encouraging them to attend scientific meetings where they can present research and make connections with others in the field. Graduate students and postdocs who have a strong interest in pursuing an academic career in psychosis research will be a strong fit for this lab.

Articles Featuring Gregory P. Strauss
Monday, September 21, 2020 - 12:37pm

Dr. Greg Strauss and his lab are among 27 international institutions collaborating to further understand phenotypes associated with the clinical high risk or prodrome state of schizophrenia in adolescents and young adults. This is the largest multisite…

Thursday, October 4, 2018 - 5:33pm

Congratulations to Dr. Katie Ehrlich and Dr. Greg Strauss who both received NARSAD Young Investigator Grants! The grants, awarded annually, support the work of early-career scientists with innovative ideas for groundbreaking neurobiological research seeking to…

Saturday, September 1, 2018 - 8:39am

Congratulations to four faculty members in the Department of Psychology who have recently received national grant awards! Keep up the great work!

My Graduate Students

Support us

We appreciate your financial support. Your gift is important to us and helps support critical opportunities for students and faculty alike, including lectures, travel support, and any number of educational events that augment the classroom experience. Click here to learn more about giving.

Every dollar given has a direct impact upon our students and faculty.